Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
At the recent Association of Community Cancer Centers’ 40th National Oncology Conference, held October 4-6 in Austin, Texas, Afreen Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, sat down for a conversation with The American Journal of Managed Care® to discuss both the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Here she discusses for whom and in what conditions e-consults are a potential mode of care access.
Transcript
Are there specific patient populations or medical conditions in which e-consults can be particularly beneficial?
I think any area within cancer care can be transformed through e-consults, whether it is psychiatry, psychology care. I think the more niche you are in practice—in the sense that if it is a cardiologist that specializes in cancer therapies and cancer care, or if it is a nephrologist that specializes in cancer therapies and kind of cancer toxicities—depending on what the needs are of the practice, really, defining that and matching that with the experts around the country is where electronic consults can be very helpful. Anywhere where you identify poor access is an opportunity where electronic consults can be very well utilized.
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More